<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891408</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-426-3988</org_study_id>
    <nct_id>NCT02891408</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function</brief_title>
  <acronym>HI</acronym>
  <official_title>A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 or Fenofibrate in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of&#xD;
      firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic&#xD;
      impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic&#xD;
      function and mild hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2016</start_date>
  <completion_date type="Actual">May 13, 2019</completion_date>
  <primary_completion_date type="Actual">May 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>Clast is defined as the last observed quantifiable concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>Tlast is defined as the time (observed time point) of Clast. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>Vz/F is defined as the apparent volume of distribution of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</measure>
    <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
    <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>First dose date plus 30 days</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following:&#xD;
Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates are the same, the AE will be considered treatment emergent.&#xD;
Any AEs leading to premature discontinuation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Laboratory Abnormalities</measure>
    <time_frame>First dose date plus 30 days</time_frame>
    <description>Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. The most severe graded abnormality from all tests was counted for each participant.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched normal hepatic function participants to mild hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched normal hepatic function participants to severe hepatic impairment participants will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched normal hepatic function participants to mild hepatic impairment participants, will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firsocostat</intervention_name>
    <description>Capsule(s) administered orally on Day 1</description>
    <arm_group_label>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</arm_group_label>
    <arm_group_label>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</arm_group_label>
    <arm_group_label>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</arm_group_label>
    <arm_group_label>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</arm_group_label>
    <arm_group_label>Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg</arm_group_label>
    <arm_group_label>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</arm_group_label>
    <other_name>GS-0976</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Tablet administered orally on Day 1</description>
    <arm_group_label>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</arm_group_label>
    <arm_group_label>Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Cohort 1 (Mild Hepatic Impairment):&#xD;
&#xD;
          -  Male and non-pregnant/non-lactating females with mildly impaired and normal hepatic&#xD;
             function.&#xD;
&#xD;
          -  Individuals will be current non-smokers (no use of tobacco, nicotine-containing or&#xD;
             tetrahydrocannabinol (THC)-containing products within the last 14 days).&#xD;
&#xD;
          -  Each individual in the control group will be matched for age (± 10 years), gender,&#xD;
             race, and body mass index (± 15% 18 ≤ body mass index (BMI) ≤ 36 kg/m^2) with an&#xD;
             individual in the mild hepatic impairment group.&#xD;
&#xD;
          -  Individuals with mild hepatic impairment must have a score of 5-6 on the&#xD;
             Child-Pugh-Turcotte (CPT) Classification at screening, have diagnosis of chronic (&gt; 6&#xD;
             months), and stable hepatic impairment with no clinically significant changes within 3&#xD;
             months (or 90 days) prior to study drug administration (Day 1).&#xD;
&#xD;
        Cohort 2 (Moderate Hepatic Impairment):&#xD;
&#xD;
          -  Male and non-pregnant/non-lactating females with moderately impaired and normal&#xD;
             hepatic function.&#xD;
&#xD;
          -  Individuals will be current non-smokers (no smoking of tobacco, nicotine-containing or&#xD;
             THC-containing products within the last 14 days).&#xD;
&#xD;
          -  Each individual in the control group will be matched for age (± 10 years), gender,&#xD;
             race, and body mass index (± 15% 18 ≤ BMI ≤ 36 kg/m^2) with an individual in the&#xD;
             moderate hepatic impairment group.&#xD;
&#xD;
          -  Individuals with moderate hepatic impairment must have a score of 7-9 on the CPT&#xD;
             Classification at screening, have diagnosis of chronic (&gt; 6 months), and stable&#xD;
             hepatic impairment with no clinically significant changes within 3 months (or 90 days)&#xD;
             prior to study drug administration (Day 1).&#xD;
&#xD;
        Cohort 3 (Severe Hepatic Impairment):&#xD;
&#xD;
          -  Male and nonpregnant/non-lactating females with severely impaired and normal hepatic&#xD;
             function.&#xD;
&#xD;
          -  Individuals will be current non-smokers (no use of tobacco, nicotine-containing or&#xD;
             THC-containing products within the last 14 days).&#xD;
&#xD;
          -  Each individual in the control group will be matched for age (± 10 years), gender,&#xD;
             race, and body mass index (± 15% 18 ≤ BMI ≤ 36 kg/m^2) with an individual in the&#xD;
             severe hepatic impairment group.&#xD;
&#xD;
          -  Individuals with severe hepatic impairment must have a score of 10-15 on the CPT&#xD;
             Classification at screening, have diagnosis of chronic (&gt; 6 months), and stable&#xD;
             hepatic impairment with no clinically significant changes within 3 months (or 90 days)&#xD;
             prior to study drug administration (Day 1).&#xD;
&#xD;
        Cohort 4 (Mild Hepatic Impairment):&#xD;
&#xD;
          -  Male and non-pregnant/non-lactating females with mildly impaired and normal hepatic&#xD;
             function.&#xD;
&#xD;
          -  Individuals will be current non-smokers (no use of tobacco, nicotine-containing or&#xD;
             THC-containing products within the last 14 days).&#xD;
&#xD;
          -  Each individual in the control group will be matched for age (± 10 years), gender,&#xD;
             race, and body mass index (± 15% 18 ≤ body mass index (BMI) ≤ 36 kg/m^2) with an&#xD;
             individual in the mild hepatic impairment group.&#xD;
&#xD;
          -  Individuals with mild hepatic impairment must have a score of 5-6 on the&#xD;
             Child-Pugh-Turcotte (CPT) Classification at screening, have diagnosis of chronic (&gt; 6&#xD;
             months), and stable hepatic impairment with no clinically significant changes within 3&#xD;
             months (or 90 days) prior to study drug administration (Day 1).&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nelson C, Weber E, Yue MS, Millward V, Qin AR, Marbury TC, et al. The Pharmacokinetics of GS-0976, an Acetyl-CoA Carboxylase (ACC) Inhibitor, in Subjects with Mild, Moderate, and Severe Hepatic Impairment [Abstract 1719]. Hepatology AASLD Abstracts 2018;68 (Suppl 1):979A-80A.</citation>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <results_first_submitted>September 3, 2020</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Firsocostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02891408/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02891408/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in United States. The first participant was screened on 23 September 2016. The last study visit occurred on 13 May 2019.</recruitment_details>
      <pre_assignment_details>In the control groups (normal hepatic function), each participant was matched for age, gender, race, and body mass index with a participant in the hepatic impairment group. 14 total unique participants with normal hepatic function were enrolled in Cohort 1 (N = 10) and Cohort 2 (N = 4). 6 participants with normal hepatic function from Cohort 1 also served as matched controls in Cohort 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
          <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
          <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1 &amp; 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
          <description>Matched normal hepatic function participants to mild or moderate hepatic impairment participants received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
          <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg</title>
          <description>Matched normal hepatic function participants to severe hepatic impairment participants received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
          <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg</title>
          <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included all participants who took at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
          <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
          <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1 &amp; 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
          <description>Matched normal hepatic function participants to mild or moderate hepatic impairment participants received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
          <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg</title>
          <description>Matched normal hepatic function participants to severe hepatic impairment participants received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
          <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg</title>
          <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="8.1"/>
                    <measurement group_id="B2" value="56" spread="9.1"/>
                    <measurement group_id="B3" value="55" spread="8.0"/>
                    <measurement group_id="B4" value="53" spread="10.8"/>
                    <measurement group_id="B5" value="54" spread="8.4"/>
                    <measurement group_id="B6" value="58" spread="6.4"/>
                    <measurement group_id="B7" value="58" spread="5.1"/>
                    <measurement group_id="B8" value="55" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>PK Analysis Sets included all enrolled participants who took at least 1 dose of study drug and had at least 1 nonmissing postdose concentration value reported by PK laboratory for corresponding analytes. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>PK Analysis Sets included all enrolled participants who took at least 1 dose of study drug and had at least 1 nonmissing postdose concentration value reported by PK laboratory for corresponding analytes. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.6" spread="158.28"/>
                    <measurement group_id="O2" value="69.8" spread="38.73"/>
                    <measurement group_id="O3" value="682.1" spread="497.09"/>
                    <measurement group_id="O4" value="64.5" spread="33.22"/>
                    <measurement group_id="O5" value="310.4" spread="75.18"/>
                    <measurement group_id="O6" value="10.2" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="57.67"/>
                    <measurement group_id="O2" value="7.4" spread="5.83"/>
                    <measurement group_id="O3" value="395.8" spread="535.93"/>
                    <measurement group_id="O4" value="5.1" spread="3.21"/>
                    <measurement group_id="O5" value="153.3" spread="65.72"/>
                    <measurement group_id="O6" value="1.4" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="61207.4" spread="24630.23"/>
                    <measurement group_id="O8" value="48128.0" spread="17377.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUClast of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric least-square mean (GLSM) ratio</param_type>
            <param_value>181</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98</ci_lower_limit>
            <ci_upper_limit>332</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUClast of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>881</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>488</ci_lower_limit>
            <ci_upper_limit>1589</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUClast of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>3081</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2446</ci_lower_limit>
            <ci_upper_limit>3881</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUClast of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>430</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>185</ci_lower_limit>
            <ci_upper_limit>998</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUClast of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>4417</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1867</ci_lower_limit>
            <ci_upper_limit>10449</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUClast of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>14676</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7932</ci_lower_limit>
            <ci_upper_limit>27153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>AUClast of Fenofibric Acid</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>122</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86</ci_lower_limit>
            <ci_upper_limit>173</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>AUCinf is defined as the concentration of drug extrapolated to infinite time. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCinf of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>AUCinf is defined as the concentration of drug extrapolated to infinite time. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.2" spread="162.71"/>
                    <measurement group_id="O2" value="70.5" spread="38.82"/>
                    <measurement group_id="O3" value="686.6" spread="499.35"/>
                    <measurement group_id="O4" value="65.8" spread="34.36"/>
                    <measurement group_id="O5" value="313.6" spread="72.68"/>
                    <measurement group_id="O6" value="10.6" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="59.21"/>
                    <measurement group_id="O2" value="8.2" spread="5.84"/>
                    <measurement group_id="O3" value="399.0" spread="537.09"/>
                    <measurement group_id="O4" value="5.9" spread="3.46"/>
                    <measurement group_id="O5" value="155.9" spread="65.85"/>
                    <measurement group_id="O6" value="1.6" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="65530.7" spread="25917.76"/>
                    <measurement group_id="O8" value="50754.1" spread="18262.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUCinf of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>183</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100</ci_lower_limit>
            <ci_upper_limit>337</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUCinf of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>869</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>482</ci_lower_limit>
            <ci_upper_limit>1568</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUCinf of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>2976</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2389</ci_lower_limit>
            <ci_upper_limit>3708</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUCinf of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>399</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>179</ci_lower_limit>
            <ci_upper_limit>892</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUCinf of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>3843</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1641</ci_lower_limit>
            <ci_upper_limit>9000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUCinf of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>10712</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6525</ci_lower_limit>
            <ci_upper_limit>17585</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>AUCinf of Fenofibric Acid</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>125</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89</ci_lower_limit>
            <ci_upper_limit>174</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>Cmax is defined as the maximum observed concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Cmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>Cmax is defined as the maximum observed concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="45.96"/>
                    <measurement group_id="O2" value="25.4" spread="20.44"/>
                    <measurement group_id="O3" value="197.7" spread="118.67"/>
                    <measurement group_id="O4" value="20.1" spread="12.09"/>
                    <measurement group_id="O5" value="73.8" spread="17.70"/>
                    <measurement group_id="O6" value="3.0" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="16.08"/>
                    <measurement group_id="O2" value="2.3" spread="2.11"/>
                    <measurement group_id="O3" value="77.3" spread="56.03"/>
                    <measurement group_id="O4" value="1.4" spread="1.16"/>
                    <measurement group_id="O5" value="31.3" spread="14.66"/>
                    <measurement group_id="O6" value="0.5" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="2723.0" spread="1078.36"/>
                    <measurement group_id="O8" value="2451.0" spread="808.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>169</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87</ci_lower_limit>
            <ci_upper_limit>326</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cmax of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>905</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>537</ci_lower_limit>
            <ci_upper_limit>1526</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Cmax of Firsocostat</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>2719</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1994</ci_lower_limit>
            <ci_upper_limit>3708</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>391</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>163</ci_lower_limit>
            <ci_upper_limit>942</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cmax of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>4470</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2170</ci_lower_limit>
            <ci_upper_limit>9207</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Cmax of GS-834773</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>9278</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4945</ci_lower_limit>
            <ci_upper_limit>17407</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Cmax of Fenofibric Acid</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM ratio</param_type>
            <param_value>109</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81</ci_lower_limit>
            <ci_upper_limit>146</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: % AUCexp of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>percentage of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="2.378"/>
                    <measurement group_id="O2" value="1.36" spread="1.222"/>
                    <measurement group_id="O3" value="0.63" spread="0.788"/>
                    <measurement group_id="O4" value="1.92" spread="1.645"/>
                    <measurement group_id="O5" value="1.35" spread="1.953"/>
                    <measurement group_id="O6" value="4.68" spread="2.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" spread="7.997"/>
                    <measurement group_id="O2" value="13.16" spread="12.642"/>
                    <measurement group_id="O3" value="1.71" spread="1.889"/>
                    <measurement group_id="O4" value="13.59" spread="12.288"/>
                    <measurement group_id="O5" value="2.21" spread="2.288"/>
                    <measurement group_id="O6" value="25.94" spread="19.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="7.11" spread="3.767"/>
                    <measurement group_id="O8" value="5.38" spread="2.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>Tmax is defined as the time (observed time point) of Cmax. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Tmax of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>Tmax is defined as the time (observed time point) of Cmax. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.02"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O5" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.50" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.02"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="2.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.50" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="3.00" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="2.50" lower_limit="2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>Clast is defined as the last observed quantifiable concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Clast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>Clast is defined as the last observed quantifiable concentration of drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.114"/>
                    <measurement group_id="O2" value="0.10" spread="0.042"/>
                    <measurement group_id="O3" value="0.26" spread="0.359"/>
                    <measurement group_id="O4" value="0.10" spread="0.047"/>
                    <measurement group_id="O5" value="0.23" spread="0.204"/>
                    <measurement group_id="O6" value="0.08" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.051"/>
                    <measurement group_id="O2" value="0.12" spread="0.070"/>
                    <measurement group_id="O3" value="0.18" spread="0.104"/>
                    <measurement group_id="O4" value="0.11" spread="0.077"/>
                    <measurement group_id="O5" value="0.22" spread="0.185"/>
                    <measurement group_id="O6" value="0.07" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="133.04" spread="51.253"/>
                    <measurement group_id="O8" value="90.71" spread="33.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>Tlast is defined as the time (observed time point) of Clast. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Tlast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>Tlast is defined as the time (observed time point) of Clast. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" lower_limit="24.00" upper_limit="72.00"/>
                    <measurement group_id="O2" value="24.00" lower_limit="24.00" upper_limit="24.00"/>
                    <measurement group_id="O3" value="72.00" lower_limit="48.00" upper_limit="96.00"/>
                    <measurement group_id="O4" value="24.00" lower_limit="24.00" upper_limit="48.00"/>
                    <measurement group_id="O5" value="48.00" lower_limit="47.97" upper_limit="72.00"/>
                    <measurement group_id="O6" value="16.00" lower_limit="12.00" upper_limit="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" lower_limit="16.00" upper_limit="72.00"/>
                    <measurement group_id="O2" value="12.00" lower_limit="10.00" upper_limit="16.00"/>
                    <measurement group_id="O3" value="48.02" lower_limit="24.00" upper_limit="96.00"/>
                    <measurement group_id="O4" value="11.00" lower_limit="10.00" upper_limit="16.00"/>
                    <measurement group_id="O5" value="36.04" lower_limit="24.00" upper_limit="48.00"/>
                    <measurement group_id="O6" value="7.00" lower_limit="6.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="96.00" lower_limit="72.00" upper_limit="96.17"/>
                    <measurement group_id="O8" value="84.25" lower_limit="72.00" upper_limit="96.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: λz of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.1093"/>
                    <measurement group_id="O2" value="0.155" spread="0.0684"/>
                    <measurement group_id="O3" value="0.096" spread="0.0753"/>
                    <measurement group_id="O4" value="0.136" spread="0.0796"/>
                    <measurement group_id="O5" value="0.077" spread="0.0204"/>
                    <measurement group_id="O6" value="0.193" spread="0.0765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" spread="0.0948"/>
                    <measurement group_id="O2" value="0.214" spread="0.0942"/>
                    <measurement group_id="O3" value="0.105" spread="0.0916"/>
                    <measurement group_id="O4" value="0.209" spread="0.0918"/>
                    <measurement group_id="O5" value="0.103" spread="0.0543"/>
                    <measurement group_id="O6" value="0.300" spread="0.1379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="0.034" spread="0.0080"/>
                    <measurement group_id="O8" value="0.038" spread="0.0082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>CL/F is defined as the apparent oral clearance following administration of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: CL/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>CL/F is defined as the apparent oral clearance following administration of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>mL/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259318.9" spread="239527.46"/>
                    <measurement group_id="O2" value="376896.2" spread="228676.47"/>
                    <measurement group_id="O3" value="59482.2" spread="63193.83"/>
                    <measurement group_id="O4" value="395572.3" spread="226508.90"/>
                    <measurement group_id="O5" value="16969.7" spread="5154.88"/>
                    <measurement group_id="O6" value="509793.4" spread="168681.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1467352.6" spread="1790413.18"/>
                    <measurement group_id="O2" value="3966285.6" spread="2982349.95"/>
                    <measurement group_id="O3" value="239748.5" spread="351882.41"/>
                    <measurement group_id="O4" value="4795605.6" spread="2952570.14"/>
                    <measurement group_id="O5" value="44379.6" spread="38793.78"/>
                    <measurement group_id="O6" value="4656562.3" spread="2689827.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="909.4" spread="539.09"/>
                    <measurement group_id="O8" value="1060.8" spread="391.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>Vz/F is defined as the apparent volume of distribution of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Vz/F of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>Vz/F is defined as the apparent volume of distribution of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2896998.5" spread="2176020.23"/>
                    <measurement group_id="O2" value="2846198.8" spread="2249997.50"/>
                    <measurement group_id="O3" value="592810.8" spread="318935.52"/>
                    <measurement group_id="O4" value="3797739.4" spread="2684509.46"/>
                    <measurement group_id="O5" value="230242.5" spread="92293.34"/>
                    <measurement group_id="O6" value="3079474.8" spread="1593778.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15576712.2" spread="19451521.66"/>
                    <measurement group_id="O2" value="19236747.1" spread="10816737.06"/>
                    <measurement group_id="O3" value="2126366.5" spread="2117217.85"/>
                    <measurement group_id="O4" value="23635388.6" spread="10179635.17"/>
                    <measurement group_id="O5" value="501512.3" spread="524040.62"/>
                    <measurement group_id="O6" value="20312673.6" spread="18230756.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="25908.5" spread="9331.48"/>
                    <measurement group_id="O8" value="28290.3" spread="8476.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
        <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
        <time_frame>Day 1: 0 (predose, ≤ 5 minutes prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose; or 72 hours of early termination from the study (if applicable)</time_frame>
        <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment participants, received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants, received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: t1/2 of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)</title>
          <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).</description>
          <population>Participants in the PK Analysis Sets were analyzed. 6 participants with normal hepatic function served as matched controls across both Cohort 1 and 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Firsocostat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" lower_limit="3.91" upper_limit="25.19"/>
                    <measurement group_id="O2" value="4.39" lower_limit="3.73" upper_limit="6.78"/>
                    <measurement group_id="O3" value="11.20" lower_limit="6.57" upper_limit="13.56"/>
                    <measurement group_id="O4" value="5.04" lower_limit="4.00" upper_limit="11.02"/>
                    <measurement group_id="O5" value="9.54" lower_limit="7.89" upper_limit="10.79"/>
                    <measurement group_id="O6" value="3.93" lower_limit="2.55" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GS-834773</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" lower_limit="3.44" upper_limit="25.28"/>
                    <measurement group_id="O2" value="3.32" lower_limit="2.58" upper_limit="3.97"/>
                    <measurement group_id="O3" value="12.82" lower_limit="4.13" upper_limit="17.25"/>
                    <measurement group_id="O4" value="3.28" lower_limit="2.88" upper_limit="3.85"/>
                    <measurement group_id="O5" value="8.51" lower_limit="6.84" upper_limit="9.19"/>
                    <measurement group_id="O6" value="2.49" lower_limit="1.78" upper_limit="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fenofibric Acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="21.33" lower_limit="17.90" upper_limit="26.43"/>
                    <measurement group_id="O8" value="18.27" lower_limit="15.73" upper_limit="21.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)</title>
        <description>Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following:&#xD;
Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates are the same, the AE will be considered treatment emergent.&#xD;
Any AEs leading to premature discontinuation of study drug.</description>
        <time_frame>First dose date plus 30 days</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed. 6 participants served as matched control across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 &amp; 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild or moderate hepatic impairment participants received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)</title>
          <description>Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following:&#xD;
Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates are the same, the AE will be considered treatment emergent.&#xD;
Any AEs leading to premature discontinuation of study drug.</description>
          <population>Participants in the Safety Analysis Set were analyzed. 6 participants served as matched control across both Cohort 1 and 2.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="30.0"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Laboratory Abnormalities</title>
        <description>Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. The most severe graded abnormality from all tests was counted for each participant.</description>
        <time_frame>First dose date plus 30 days</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed. 6 participants served as matched control across both Cohort 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
            <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 &amp; 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
            <description>Matched normal hepatic function participants to mild or moderate hepatic impairment participants received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
            <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (Normal Hepatic Function): Firsocostat 5 mg</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment participants received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
            <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (Normal Hepatic Function): Fenofibrate 48 mg</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Laboratory Abnormalities</title>
          <description>Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. The most severe graded abnormality from all tests was counted for each participant.</description>
          <population>Participants in the Safety Analysis Set were analyzed. 6 participants served as matched control across both Cohort 1 and 2.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="90.0"/>
                    <measurement group_id="O7" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose date plus 30 days</time_frame>
      <desc>Participants in the Safety Analysis Set were analyzed. 6 participants served as matched control across both Cohort 1 and 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg</title>
          <description>Participants with mild hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg</title>
          <description>Participants with moderate hepatic impairment received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1 &amp; 2 (Normal Hepatic Function): Firsocostat 20 mg</title>
          <description>Matched normal hepatic function participants to mild or moderate hepatic impairment participants received a single dose of firsocostat 20 mg (2 × 10 mg capsules) orally on Day 1</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg</title>
          <description>Participants with severe hepatic impairment received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg</title>
          <description>Matched normal hepatic function participants to severe hepatic impairment participants received a single dose of firsocostat 5 mg (1 × 5 mg capsule) orally on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg</title>
          <description>Participants with mild hepatic impairment received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg</title>
          <description>Matched normal hepatic function participants to mild hepatic impairment participants, received a single dose of fenofibrate 48 mg (1 × 48 mg tablet) orally on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

